Association of alirocumab therapy with inflammatory lesions of the vocal folds: A case report

Peter A. Benedict; Rania M. Abdou; Gregory R. Dion; Peak Woo; Ryan C. Branski; Milan R. Amin

doi:10.1002/lary.26426

Association of alirocumab therapy with inflammatory lesions of the vocal folds: A case report

Peter A. Benedict, Rania M. Abdou, Gregory R. Dion, Peak Woo, Ryan C. Branski, Milan R. Amin

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Therapeutic monocolonal antibodies (MAbs) are a new, rapidly growing class of medications that frequently have poorly characterized side-effect profiles. We present a patient who developed inflammatory lesions of the vocal folds in temporal relation to the initiation of alirocumab. Lesions of the vocal folds represent a previously unreported adverse effect of alirocumab therapy, making it the second MAb documented with such a side effect. The potential laryngeal effects of alirocumab specifically, and of MAbs more broadly, warrant investigation. Laryngoscope, 127:1652–1654, 2017.

Original language	English
Pages (from-to)	1652-1654
Number of pages	3
Journal	Laryngoscope
Volume	127
Issue number	7
DOIs	https://doi.org/10.1002/lary.26426
State	Published - Jul 2017

Keywords

Larynx
adverse effect
alirocumab
laryngeal lesion
monoclonal antibody

Access to Document

10.1002/lary.26426

Cite this

@article{f977d1e0fccf403ab016b36d51869360,

title = "Association of alirocumab therapy with inflammatory lesions of the vocal folds: A case report",

abstract = "Therapeutic monocolonal antibodies (MAbs) are a new, rapidly growing class of medications that frequently have poorly characterized side-effect profiles. We present a patient who developed inflammatory lesions of the vocal folds in temporal relation to the initiation of alirocumab. Lesions of the vocal folds represent a previously unreported adverse effect of alirocumab therapy, making it the second MAb documented with such a side effect. The potential laryngeal effects of alirocumab specifically, and of MAbs more broadly, warrant investigation. Laryngoscope, 127:1652–1654, 2017.",

keywords = "Larynx, adverse effect, alirocumab, laryngeal lesion, monoclonal antibody",

author = "Benedict, {Peter A.} and Abdou, {Rania M.} and Dion, {Gregory R.} and Peak Woo and Branski, {Ryan C.} and Amin, {Milan R.}",

note = "Publisher Copyright: {\textcopyright} 2016 The American Laryngological, Rhinological and Otological Society, Inc.",

year = "2017",

month = jul,

doi = "10.1002/lary.26426",

language = "English",

volume = "127",

pages = "1652--1654",

journal = "Laryngoscope",

issn = "0023-852X",

publisher = "Wiley-Blackwell",

number = "7",

}

TY - JOUR

T1 - Association of alirocumab therapy with inflammatory lesions of the vocal folds

T2 - A case report

AU - Benedict, Peter A.

AU - Abdou, Rania M.

AU - Dion, Gregory R.

AU - Woo, Peak

AU - Branski, Ryan C.

AU - Amin, Milan R.

PY - 2017/7

Y1 - 2017/7

N2 - Therapeutic monocolonal antibodies (MAbs) are a new, rapidly growing class of medications that frequently have poorly characterized side-effect profiles. We present a patient who developed inflammatory lesions of the vocal folds in temporal relation to the initiation of alirocumab. Lesions of the vocal folds represent a previously unreported adverse effect of alirocumab therapy, making it the second MAb documented with such a side effect. The potential laryngeal effects of alirocumab specifically, and of MAbs more broadly, warrant investigation. Laryngoscope, 127:1652–1654, 2017.

AB - Therapeutic monocolonal antibodies (MAbs) are a new, rapidly growing class of medications that frequently have poorly characterized side-effect profiles. We present a patient who developed inflammatory lesions of the vocal folds in temporal relation to the initiation of alirocumab. Lesions of the vocal folds represent a previously unreported adverse effect of alirocumab therapy, making it the second MAb documented with such a side effect. The potential laryngeal effects of alirocumab specifically, and of MAbs more broadly, warrant investigation. Laryngoscope, 127:1652–1654, 2017.

KW - Larynx

KW - adverse effect

KW - alirocumab

KW - laryngeal lesion

KW - monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=85006786160&partnerID=8YFLogxK

U2 - 10.1002/lary.26426

DO - 10.1002/lary.26426

M3 - Article

C2 - 27933632

AN - SCOPUS:85006786160

SN - 0023-852X

VL - 127

SP - 1652

EP - 1654

JO - Laryngoscope

JF - Laryngoscope

IS - 7

ER -

Association of alirocumab therapy with inflammatory lesions of the vocal folds: A case report

Abstract

Keywords

Access to Document

Fingerprint

Cite this